293 related articles for article (PubMed ID: 23730873)
1. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.
Acquazzino MA; Fischer RT; Langnas A; Coulter DW
Pediatr Transplant; 2013 Aug; 17(5):466-71. PubMed ID: 23730873
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune hemolytic anemia in pediatric liver or combined liver and small bowel transplant patients: a case series and review of the literature.
Li M; Goldfinger D; Yuan S
Transfusion; 2012 Jan; 52(1):48-54. PubMed ID: 21790626
[TBL] [Abstract][Full Text] [Related]
3. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
5. Cold agglutinin syndrome in pediatric liver transplant recipients.
Wong W; Merker JD; Nguyen C; Berquist W; Jeng M; Viele M; Glader B; Fontaine MJ
Pediatr Transplant; 2007 Dec; 11(8):931-6. PubMed ID: 17976131
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia.
Valentini RP; Imam A; Warrier I; Ellis D; Ritchey AK; Ravindranath Y; Shapiro R; Moritz ML
Pediatr Transplant; 2006 May; 10(3):358-61. PubMed ID: 16677361
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune cytopaenia after paediatric intestinal transplantation: a case series.
Botija G; Ybarra M; Ramos E; Molina M; Sarría J; Martínez-Ojinaga E; Andrés AM; López-Santamaría M; Prieto G
Transpl Int; 2010 Oct; 23(10):1033-7. PubMed ID: 20444240
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature.
Miloh T; Arnon R; Roman E; Hurlet A; Kerkar N; Wistinghausen B
Pediatr Transplant; 2011 Dec; 15(8):870-8. PubMed ID: 22112003
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
Zeier M; Van Der Giet M
Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
13. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
Vallin M; Guillaud O; Morard I; Gagnieu MC; Mentha G; Adham M; Morelon E; Boillot O; Giostra E; Dumortier J
Clin Transplant; 2011; 25(4):660-9. PubMed ID: 21158921
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
17. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hemolytic anemia in patients with liver transplants for primary biliary cirrhosis: Three case reports and a review of the literature.
Retana AK; Kaplan MM; Erban JK
Am J Gastroenterol; 2007 Jan; 102(1):197-200. PubMed ID: 17037996
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
[TBL] [Abstract][Full Text] [Related]
20. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
